TIER III HALLMARKS

Tier III: The Integrative Hallmarks (Systemic Failure)

These are the downstream, system-wide failures that arise as a consequence of the accumulated molecular and cellular damage in Tiers 1 and 2, representing the failure of the whole organism.

One key line of research focuses on niche repair—restoring the specific microenvironment in which stem cells live. Researchers at the Buck Institute for Research on Aging, and the lab of Dr. Irina Conboy at UC Berkeley, demonstrated that a systemic intervention like parabiosis (sharing blood circulation between old and young mice) could significantly rejuvenate the stem cell function in multiple tissues of the older animal. This work proved that there are circulating factors in young blood that can fundamentally restore stem cell vitality. Companies like Elevian are commercializing research focused on identifying and isolating these youthful factors, such as GDF11, for therapeutic delivery.

The cutting edge, however, involves combining this with cellular replacement—directly introducing fresh, functional cells into the system. For example, the groundbreaking 2025 primate study by Lei et al. demonstrated significant systemic rejuvenation by administering engineered mesenchymal stem cells (MSCs). This proved that cells, once repaired or enhanced (in this case, CRISPR-Cas9 edited to be resistant to the hostile aged environment), can be successfully re-introduced to restore tissue function.

The scientific consensus is that the next generation of therapy will combine these two approaches: repairing the niche (cleaning up the SASP environment) while also selectively replacing the stem cell population with engineered, high-functioning cells.

Conboy, I. M., Conboy, M. J., Wagers, A. J., Girma, E. R., Weissman, I. L., & Rando, T. A. (2005). Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature, 433(7027), 760–764. https://doi.org/10.1038/nature03260

Sinha, M., Jang, Y. C., Oh, J., Khong, D., Wu, E. Y., Manohar, R., ... & Wagers, A. J. (2014). Restoring systemic GDF11 levels reverses age-related dysfunction in skeletal muscle. Science, 344(6184), 649–652. https://doi.org/10.1126/science.1251152

Lei, J., Xin, Z., Chen, H., Wang, S., Zhang, W., ... & Liu, G. H. (2025). Reprogramming aging: Genetically enhanced mesenchymal progenitor cells show systemic rejuvenation in primates. Cell, 188(1), 1–22.

Therapies aim to block these disruptive inflammatory signals that interfere with communication, often by successfully addressing the root cause, which is cellular senescence. Progress is focused on small molecule senomorphics. These compounds are designed to suppress toxic SASP secretion instead of killing the cell (as senolytics do), effectively silencing the damage without removing the cell itself. This offers an alternative, potentially safer, approach to quieting the hostile inflammatory noise that disrupts systemic communication.

The Mayo Clinic and various pharmaceutical groups are developing these senomorphic agents. A significant accomplishment is the identification of specific glucocorticoid receptor modulators that specifically shut down SASP production, offering a potent pharmacological means to restore youthful communication channels without the systemic drawbacks of full immune suppression. Additionally, research into reversing extracellular matrix (ECM) stiffness, a major component of communication failure, is being conducted by groups like AgeX Therapeutics, which focuses on restoring youthful tissue mechanics.

Laberge, R. M., Zhou, L., Sarantos, M. R., Rodier, F., Freund, A., de Keizer, P. L., ... & Campisi, J. (2012). Glucocorticoids suppress selected components of the senescence-associated secretory phenotype. Aging Cell, 11(5), 810–818. https://doi.org/10.1111/j.1474-9726.2012.00841.x

AgeX Therapeutics. (n.d.). iTR™: Induced tissue regeneration. Retrieved December 16, 2025, from https://www.agexinc.com/technology/

Often termed 'inflammaging,' this is a persistent, low-grade, sterile inflammation (triggered by internal cellular debris rather than infection) that acts as a background noise, damaging healthy tissue over time and contributing to atherosclerosis, frailty, and cognitive decline. It is targeted primarily through anti-inflammatory diets, exercise, and pharmaceutical anti-inflammatories aimed at cooling this systemic immune over-reaction. The farthest progress involves the development of highly specific inflammasome inhibitors (such as MCC950 or the orally active Dapansutrile), particularly targeting the NLRP3 inflammasome—the key molecular switch that triggers chronic, damaging inflammation. Success in this area is viewed as a high-impact breakthrough because it offers the ability to therapeutically halt the core engine of chronic, sterile inflammation.

The pharmaceutical company Novartis conducted a landmark trial (CANTOS) on the anti-inflammatory drug Canakinumab, which targeted interleukin-1beta. While the drug didn't achieve its primary cardiovascular endpoint, it showed a significant reduction in lung cancer mortality, providing the first clinical proof that targeting an inflammatory pathway can fundamentally alter age-related disease trajectories. Today, startups are working on NLRP3 inhibitors that promise to extinguish chronic systemic inflammation without broadly compromising the host’s ability to fight acute infections.

Lampi, M. C., & Reinhart-King, C. A. (2018). Targeting extracellular matrix stiffness to attenuate disease: From molecular mechanisms to clinical trials. Science Translational Medicine, 10(422), eaao0475. https://doi.org/10.1126/scitranslmed.aao0475 

This is arguably the most accessible intervention point, targeted via probiotics, prebiotics, and specific diet modifications to restore a diverse and beneficial microbial ecosystem. The cutting edge is the study of targeted microbial therapeutics and the use of Fecal Microbiota Transplants (FMT). Researchers at the University College Cork and the APC Microbiome Ireland demonstrated that FMT from young mice into aged mice reversed age-related changes in the gut, brain, and immune system of the recipients.

This finding proves that the gut biome contains powerful information that can be transferred, providing an immediate and potent mechanism for reversing systemic aging phenotypes. This has accelerated the development of precision postbiotics—the beneficial metabolic byproducts of microbial fermentation—that can be delivered directly to the body. Companies like Gubra and Microbiome Insights are leading the charge, working to develop treatments that utilize specific bacterial strains to reduce inflammation and restore gut barrier integrity in the aged.

Boehme, M., Guzzetta, K. E., Bastiaanssen, T. F. S., van de Wouw, M., Moloney, G. M., Gual-Grau, A., ... & Cryan, J. F. (2021). Microbiota from young mice counteracts selective age-associated behavioral deficits. Nature Aging, 1(8), 666–676. https://doi.org/10.1038/s43587-021-00093-9